opioid growth factor
Recombinant proteinexperimental
Met-enkephalin, also known as metenkefalin (INN), sometimes referred to as opioid growth factor (OGF), is a naturally occurring, endogenous opioid peptide that has opioid effects of a relatively short duration. It is one of the two forms of enkephalin, the other being leu-enkephalin. The enkephalins are considered to be the primary endogenous ligands of the δ-opioid receptor, due to their high potency and selectivity for the site over the other endogenous opioids. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2003 (NCT00109941)
Timeline
Indications
Mechanism of action
- Proenkephalin-ASupplementation
PENK supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMet-enkephalin ↗
Also known as
- opioid growth factor
- opioid growth factor
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00783172 | Phase 1 | Jan 1, 2009 | National Cancer Institute (NCI), National Institutes of Health (NIH), Pennsylvania State University |
| NCT00982696 | Phase 2 | Feb 1, 2008 | Pennsylvania State University |
| NCT00109941 | Phase 2 | Oct 1, 2003 | Pennsylvania State University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pennsylvania State University | Academic/Hospital | 3 | 3 | 2 | 2003 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2009 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2009 |
3 organizations
Page 1 / 1